Eh301 (nicotinamide riboside/pterostilbene) (DrugBank: Nicotinamide, Nicotinamide riboside)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04562831 (ClinicalTrials.gov) | October 7, 2020 | 10/9/2020 | The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS. | A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Study | Amyotrophic Lateral Sclerosis | Dietary Supplement: EH301 (Nicotinamide Riboside/Pterostilbene) | Haukeland University Hospital | NULL | Recruiting | 35 Years | N/A | All | 380 | N/A | Norway |